BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 15990461)

  • 1. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy.
    Sydorova M; Lee MS
    Ophthalmic Res; 2005; 37(4):188-90. PubMed ID: 15990461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
    Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
    Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
    Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J
    Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy.
    Mohan N; Monickaraj F; Balasubramanyam M; Rema M; Mohan V
    J Diabetes Complications; 2012; 26(5):435-41. PubMed ID: 22699109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of RAGE and its ligands in proliferative retinal disease.
    Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
    Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
    Itakura H; Kishi S; Kotajima N; Murakami M
    Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
    Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
    Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
    Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
    Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy.
    Wang X; Wang G; Wang Y
    Am J Ophthalmol; 2009 Dec; 148(6):883-9. PubMed ID: 19837381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble TNF receptors in vitreoretinal proliferative disease.
    Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
    Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a systemic angiotensin receptor blocker on vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy.
    Byon IS; Jeon HS; Kim HW; Lee SJ; Lee JE; Oum BS
    Curr Eye Res; 2013 Jul; 38(7):774-80. PubMed ID: 23725216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A comparative study of vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy].
    Zhou H; Zhang H
    Zhonghua Yan Ke Za Zhi; 1997 Jul; 33(4):247-50. PubMed ID: 10451953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II.
    Funatsu H; Yamashita H; Noma H; Mimura T; Sakata K; Hori S
    Br J Ophthalmol; 2004 Aug; 88(8):1064-8. PubMed ID: 15258026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between ficolin-3 and vascular endothelial growth factor-to-pigment epithelium-derived factor ratio in the vitreous of eyes with proliferative diabetic retinopathy.
    Zheng B; Li T; Chen H; Xu X; Zheng Z
    Am J Ophthalmol; 2011 Dec; 152(6):1039-43. PubMed ID: 21851923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease.
    Murugeswari P; Shukla D; Rajendran A; Kim R; Namperumalsamy P; Muthukkaruppan V
    Retina; 2008 Jun; 28(6):817-24. PubMed ID: 18536597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y; Zhang Y; Zhao T; Jiang YR
    Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy.
    Burgos R; Simó R; Audí L; Mateo C; Mesa J; García-Ramírez M; Carrascosa A
    Diabetologia; 1997 Sep; 40(9):1107-9. PubMed ID: 9300249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
    Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
    Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy.
    Zhou J; Wang S; Xia X
    Curr Eye Res; 2012 May; 37(5):416-20. PubMed ID: 22409294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic shift in vitreous after vitrectomy in patients with proliferative diabetic retinopathy.
    Yoshida S; Nakama T; Ishikawa K; Arima M; Tachibana T; Nakao S; Sassa Y; Yasuda M; Enaida H; Oshima Y; Kono T; Ishibashi T
    Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):6997-7003. PubMed ID: 22977138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.